methyl 2-[3-(6-acetamidonaphthalen-2-yl)prop-2-enoylamino]benzoate | 1146206-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-[3-(6-acetamidonaphthalen-2-yl)prop-2-enoylamino]benzoate
• CAS: 1146206-16-7
• 化学式: C₂₃H₂₀N₂O₄
• 分子量: 388.423
• InChiKey: IYUPSFQYIZYXTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.24
• 重原子数：
  29.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  84.5
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  methyl 2-[3-(6-acetamidonaphthalen-2-yl)prop-2-enoylamino]benzoate 在 palladium 10% on activated carbon 、 氢气 、 palladium(II) hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、310.27 kPa 条件下， 以33%的产率得到Methyl 2-[3-(6-acetamidonaphthalen-2-yl)propanoylamino]benzoate
  参考文献：
  名称：

  Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats

  摘要：

  Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were discovered with excellent in vitro activity. Compound 2g displayed a good therapeutic index regarding free fatty acids (FFA) reduction and vasodilation effects in rats, with very weak cytochrome P450 2C8 (CYP2C8) and cytochrome P450 2C9 (CYP2C9) inhibition, and a good mouse pharmacokinetics (PK) profile.

  DOI：

  10.1021/jm900151e
• 作为产物：
  描述：

  methyl 2-acrylamidobenzoate 、 N-(6-bromonaphthalen-2-yl)acetamide 在 四丁基氯化铵 、 palladium diacetate 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以51%的产率得到methyl 2-[3-(6-acetamidonaphthalen-2-yl)prop-2-enoylamino]benzoate
  参考文献：
  名称：

  Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats

  摘要：

  Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were discovered with excellent in vitro activity. Compound 2g displayed a good therapeutic index regarding free fatty acids (FFA) reduction and vasodilation effects in rats, with very weak cytochrome P450 2C8 (CYP2C8) and cytochrome P450 2C9 (CYP2C9) inhibition, and a good mouse pharmacokinetics (PK) profile.

  DOI：

  10.1021/jm900151e